ET-traps: Potential therapeutics for preeclampsia

Arjun Jain; Ira Jain

doi:10.1016/j.drudis.2023.103787

ET-traps: Potential therapeutics for preeclampsia

Drug Discov Today. 2023 Nov;28(11):103787. doi: 10.1016/j.drudis.2023.103787. Epub 2023 Sep 22.

Authors

Arjun Jain¹, Ira Jain²

Affiliations

¹ ET-traps, Cambridge, UK; Department of Physiology, Development and Neuroscience, University of Cambridge, UK; Accelerate Cambridge, Judge Business School, University of Cambridge, UK; Imperial College London, UK.
² ET-traps, Cambridge, UK; Indian Institute of Management, Ahmedabad, India; National University of Singapore, Singapore. Electronic address: ira@et-traps.co.uk.

PMID: 37742912
DOI: 10.1016/j.drudis.2023.103787

Abstract

Elevated endothelin-1 (ET-1) has been implicated in several diseases including preeclampsia, where it causes the induction of hypertension, oxidative stress, endoplasmic reticulum stress, microvascular dysfunction and tissue damage in different organs. ET-traps are Fc-fusion proteins with a design based on the physiological receptors of ET-1. This paper discusses the potential use of ET-traps as a therapeutic for preeclampsia. ET-traps potently bind and sequester pathologically elevated ET-1 to significantly reduce different markers of pathology to non-disease levels with no toxicity.

Keywords: ER stress; ET-traps; cardiovascular complications; endothelin-1; oxidative stress; preeclampsia; proteinuria.

MeSH terms

Endothelin-1
Female
Humans
Hypertension*
Oxidative Stress
Pre-Eclampsia*
Pregnancy

Substances

Endothelin-1